Tillotson Martin Tami's most recent trade in Supernus Pharmaceuticals Inc was a trade of 1,250 Common Stock done . Disclosure was reported to the exchange on Feb. 23, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Tillotson Tami Martin | Sr. V.P., Regulatory Affairs | 23 Feb 2024 | 1,250 | 87,418 (0%) | 0% | 0 | Common Stock | ||
| Supernus Pharmaceuticals Inc | Tillotson Martin Tami | Sr. V.P., Regulatory Affairs | 23 Feb 2024 | 1,250 | 3,750 | - | - | Restricted Stock Unit | ||
| Supernus Pharmaceuticals Inc | Tami Martin Tillotson | Sr. V.P., Regulatory Affairs | 23 Feb 2024 | 485 | 86,933 (0%) | 0% | 29.1 | 14,094 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tillotson Martin Tami | Sr. V.P., Regulatory Affairs | 22 Feb 2024 | 750 | 1,500 | - | - | Restricted Stock Units | ||
| Supernus Pharmaceuticals Inc | Martin Tillotson Tami | Sr. V.P., Regulatory Affairs | 22 Feb 2024 | 750 | 86,414 (0%) | 0% | 0 | Common Stock | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2024 | 246 | 86,168 (0%) | 0% | 27.9 | 6,873 | Common Stock | |
| Supernus Pharmaceuticals Inc | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 10 Jan 2024 | 8,000 | 0 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 10 Jan 2024 | 8,000 | 85,664 (0%) | 0% | 27.9 | 223,280 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Martin Tillotson | Sr. V.P., Regulatory Affairs | 10 Jan 2024 | 8,000 | 93,664 (0%) | 0% | 9.2 | 73,920 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 25 Aug 2023 | 5,135 | 85,249 (0%) | 0% | 31.6 | 162,215 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 23 Feb 2023 | 20,000 | 20,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 23 Feb 2023 | 5,000 | 5,000 | - | - | Restricted Stock Units | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2023 | 750 | 90,323 (0%) | 0% | 0 | Common Stock | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2023 | 750 | 2,250 | - | - | Restricted Stock Units | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2023 | 289 | 90,034 (0%) | 0% | 38.6 | 11,147 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 16 Feb 2023 | 1,500 | 0 | - | - | Performance Share Unit | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 16 Feb 2023 | 1,500 | 88,720 (0%) | 0% | 0 | Common Stock | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 12 Jan 2023 | 1,500 | 1,500 | - | - | Performance Share Unit | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Aug 2022 | 5,000 | 87,220 (0%) | 0% | 36.0 | 179,900 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Aug 2022 | 5,000 | 0 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Aug 2022 | 5,000 | 92,220 (0%) | 0% | 7.9 | 39,500 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 04 Aug 2022 | 5,000 | 92,220 (0%) | 0% | 7.9 | 39,500 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 04 Aug 2022 | 5,000 | 5,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 04 Aug 2022 | 5,000 | 87,220 (0%) | 0% | 33.0 | 164,900 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2022 | 18,000 | 18,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 22 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 6,250 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 89,451 (0%) | 0% | 13.0 | 40,563 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 86,326 (0%) | 0% | 30.0 | 93,702 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 89,451 (0%) | 0% | 13.0 | 40,563 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 86,326 (0%) | 0% | 32.0 | 99,938 | Common Stock | |
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 13 Apr 2021 | 3,125 | 9,375 | - | - | Employee Stock Option (Right to Buy) | ||
| Supernus Pharmaceuticals Inc | Tami Tillotson Martin | Sr. V.P., Regulatory Affairs | 19 Feb 2021 | 17,000 | 17,000 | - | - | Employee Stock Option (Right to Buy) |